INTRODUCTION

Even though obstructive sleep apnea (OSA) was recognized as a clinical entity nearly 35 years ago\(^1\,^2\), awareness regarding this condition outside the domain of sleep medicine was slow to evolve. Increasing awareness regarding sleep disordered breathing and wider availability of sleep laboratories have resulted in a spurt in the research in sleep disordered breathing from several parts of the world including India. Still, OSA remains largely unrecognised and undiagnosed\(^2\). The reasons for failure to recognise the syndrome include lack of training in sleep medicine, a general lack of awareness, and the non-availability and cost involved in the diagnostic work-up of a patient with suspected OSA. Since OSA is common, it has considerable effects upon patients and their families, it increases the risk of other diseases, and can be effectively treated. It is important to improve the way these patients are diagnosed. In this review, we have attempted to summarize the current understanding regarding the pathogenesis, clinical presentation, diagnosis, and therapeutic options for patients with OSA.

DEFINITION

The obstructive sleep apnea syndrome (OSAS) is defined as sleep disordered breathing associated with daytime symptoms, most often excessive sleepiness\(^3\). According to the consensus statement of the American Academy of Sleep Medicine Task Force\(^3\,^4\), an apnea involves upper-airway collapse, and is defined as nearly complete cessation of airflow associated with oxygen desaturation or an arousal from sleep. Hypopnea, which is associated with partial collapse of the upper airway is considered to be existing on a pathologic continuum with apnea.

The condition is usually associated with loud snoring and hypoxemia, and apneas are typically terminated by brief arousals, which result in marked sleep fragmentation and diminished slow wave sleep (SWS) and rapid eye movement (REM) sleep. Patients with OSA are usually unaware of this sleep disruption, but the changes in sleep architecture contribute significantly to the prominent symptom of chronic daytime sleepiness found in these patients\(^4\).

Conventionally, the apnea–hypopnea index (AHI) which measures the frequency of reductions in airflow associated with upper-airway collapse or narrowing that occurs with the state change from wakefulness to sleep has been used to characterize OSA. However, though AHI measures the frequency of disordered breathing events, it does not quantify other processes that may be operative in the pathophysiology of OSA\(^4\,^5\).

However, upper airway narrowing with sleep onset is a normal phenomenon and several factors such as obesity, craniofacial abnormalities among others may accentuate it. These accentuating phenomena are not “all or none” in nature, and thus upper airway narrowing during sleep is a continuously variable phenomenon within a population and, indeed, to some extent across nights within an individual\(^4\,^5\).

EPIDEMIOLOGY

In most of the studies, AHI of 5 or more determined by overnight PSG in a patient with daytime sleepiness, disturbed or unrefreshed sleep has been considered as the diagnostic criteria for OSAS\(^6\,^7\). Prevalence of OSA in various studies published from abroad and India\(^8\,^9\) are listed in Table 1.
Diagnosis and Treatment of Obstructive Sleep Apnea

759

Risk Factors

Review of published literature suggests that several risk factors are associated with the development of OSA. These are listed in Table 2.

**PATHOGENESIS: NEWER INSIGHTS**

Recurrent occurrence of upper airway occlusion during sleep produces OSA. This is thought to be the result of a variety of physiological characteristics. Patients with OSA have an anatomically small upper airway with augmented pharyngeal dilator muscle activation maintaining airway patency while awake, but not during sleep. Variation in the individual phenotypic characteristics in the upper airway anatomy; the ability of upper airway dilator muscles to respond to rising intrapharyngeal negative pressure and increasing carbon dioxide during sleep; arousal threshold in response to respiratory stimulation, and ventilatory control instability are the factors that are thought to determine the development and severity of OSA in the individual patient.

**Molecular Basis of Somnogenesis**

Accumulating evidence also points to the bidirectional, feed forward, pernicious association between sleep apnea, sleepiness, inflammation, and insulin resistance—all promoting atherosclerosis and cardiovascular disease. Data are available linking circulating nuclear factor-κB (NF-κB)–dependent genes, tumor necrosis factor-α (TNF-α), and interleukin-8 (IL-8) to OSA. Evidence is available suggesting that the pro-inflammatory cytokine TNF-α is somnogenic and is independently associated with daytime sleepiness. Patients with OSA have elevated circulating levels of TNF-α and it has also been demonstrated that OSA is associated with the TNF-α (-308A) gene polymorphism, which results in increased TNF-α production. In a recently published study, it was reported that, on multivariate analysis, TNF-α was independently associated with the desaturation index (p<0.001), Epworth Sleepiness Score (p=0.005); and CPAP therapy lowered TNF-α levels (p=0.004).

**CLINICAL MANIFESTATIONS**

**Historical Perspective**

References to OSA have been found in the Hippocratic Corpus (V-IV century BC). The Roman author Pliny the Younger (79 AD) reported the death of a man with obesity, sleepiness, and snoring. The account of “Fat Joe”, the famous character of Charles Dickens’s Pickwick Papers, an obese person who fell asleep during daytime while performing even extremely simple tasks is a lucid description of a person affected by OSA. Distinguished personalities such as Emperor Napoleon Bonaparte, Queen Victoria, and President Franklin D. Roosevelt were victims of this malady.

Since the pathophysiological consequences of OSA can virtually affect almost every organ system in the body, it is not surprising that patients with OSA present to several specialists and clinicians. Patients with OSA present with daytime and night-time symptoms...
Bed partners of patients with OSA often provide useful information regarding the nocturnal symptoms. Snoring is the most frequently reported nocturnal symptom. It is usually loud and intermittent with periods of silence (apnea) despite the ventilatory efforts of the chest and abdomen. Prevalence of OSA has been reported to be 35 to 64% in habitual snorers. Nocturnal polyuria is frequent—may be the result of increased atrial natriuretic peptide secretion due to increased stretch on the right atrial wall due to swings in negative intrathoracic pressure.

Excessive daytime sleepiness, the principal symptom in patients with OSA, appears to result from sleep fragmentation due to recurrent central nervous system arousals in response to disordered breathing events. Morning headaches may reflect hypercapnia and the consequences of obesity hyperventilation syndrome. Altered levels of sexual hormones and pudendal neuropathy may result in sexual dysfunction. High negative intrathoracic pressures during apnea, and effect of hypoxia on the gastro-esophageal sphincter may result in increased occurrence of gastro-esophageal reflux.

Driving is considered to be a complex task involving distinct cognitive, perceptual, motor, and decision making skills. Driving not only involves ensuring speed and lane control, but also monitoring the speed. To safely do this requires careful attention and alertness which can be problematic for patients with OSA. It is not surprising therefore that OSA patients have an increased rate of automobile accidents.

Consequences of OSA

The tremendous impact of the cardiovascular and neurocognitive pathophysiological consequences of OSA is increasingly being recognized. The consequences of OSA are being increasingly understood and are listed in Table 4, and recent evidence regarding some of them are discussed hereinafter.
independent cardiovascular risk which is reduced by effective treatment of OSA. In a recently published study, multivariate analysis revealed that untreated severe OSA significantly increased the risk of fatal (OR 2.87, 95% CI 1.17-7.51) and non-fatal (OR 3.17, 95% CI 1.12-7.51) cardiovascular events compared with healthy subjects. It was also observed that CPAP treatment reduced this risk.

Atherosclerosis

In patients with OSA, acceleration of atherosclerosis may result due to episodic hypoxemia, chronic sympathetic hyperactivity, elevated levels of fibrinogen and homocysteine, pulmonary hypertension and consequent risk for right heart hypertrophy and heart failure; increased risk of plaque ruptures and subsequent cardiovascular or cerebrovascular events.

Sudden Cardiac Death

Patients with OSA are known to have severe perturbations of autonomic, hemodynamic, humoral, and vascular regulation during sleep, and OSA is being recognized as an important treatable cause of sudden death. In the general population, the risk of sudden death from cardiac causes is significantly greater during the morning hours after waking (i.e. from 6 a.m. to noon), compared with the period during sleep from midnight to 6 a.m. In patients with OSA, the reverse was observed, and the relative risk of sudden death from cardiac causes from midnight to 6 a.m. was 2.57 (95% CI, 1.87 to 3.52) in a study carried out in OSA subjects from Minnesota.

Neurocognitive Dysfunction

Neurocognitive dysfunction is an important consequence of OSA. Magnetic resonance spectroscopy (MRS) has been applied for detecting abnormalities and their significance and correction with CPAP intervention.

Erectile Dysfunction

Erectile dysfunction, a common problem in patients with OSA has been shown to improve considerably over a short-term with CPAP treatment.

Sleep Deprivation

The consequences of sleep deprivation are a subject of investigation recently. Sleep deprivation, especially in working adolescents and young resident doctors is considered to be a hidden health hazard. Sleep deprivation is also believed to worsen OSA. In a study published from Australia, subjects with OSA showed a lower minimum oxygen saturation following sleep deprivation. The authors reported that, while acute sleep deprivation did not worsen most OSA parameters as measured by PSG, a lower minimum oxygen saturation after sleep deprivation may be important in patients with mild OSA and significant cardiorespiratory disease. These issues merit further study.

Diagnosis

The diagnosis of OSA is based on the characteristic clinical presentation together with objective demonstration of sleep disordered breathing.

Clinical Evaluation

A detailed history and thorough clinical examination is the initial step in the evaluation of a patient with suspected OSA. It should be remembered, however, that none of the common presenting clinical features alone has sufficient discriminatory value to make an accurate diagnosis, and combining constellations of symptoms can improve diagnostic accuracy. Loud snoring and witnessed apneas have been reported to identify OSA with a sensitivity of 78% and a specificity of 67%. Oropharyngeal and cranial anatomical abnormalities such as tonsillar hypertrophy, enlargement of soft palate, or tongue, retrognathia or micrognathia, should all alert the clinician towards the possibility of OSA. Current evidence does not mandate the use of routine upper airway imaging for the diagnosis of OSA. While obesity is an important risk factor for OSA, nearly half the patients with OSA may not be obese. Neck circumference (>43 cm in males and >41 cm in females) reflecting the upper body obesity has been associated with a high risk of OSA.

Assessment of Daytime Somnolence

Daytime somnolence has been studied using instrumental and non-instrumental tests. Commonly used instruments for the evaluation of daytime somnolence include multiple sleep latency test (MSLT), maintenance of wakefulness test (MWT), driving simulators, among others. MSLT consists of a series of sleep recordings under standardized conditions that measure the latency of sleep onset and occurrence of REM sleep. In MWT, a series of sleep recordings are obtained under standard conditions while the subject attempts to stay awake in a quiet room. Non-instrumental test questionnaires such as the Stanford Sleepiness Scale (SSS) and the Epworth Sleepiness Scale (ESS),
administration of modified Berlin questionnaire prior to PSG study have been found to be useful in identifying high-risk subjects and in avoiding unnecessary PSG studies especially in resource-limited settings38.

Prediction Models

Several prediction models have been developed to accurately predict OSA using self-reported symptoms combined with demographic and anthropometric data11,39. One such model has been developed and validated in overtly asymptomatic obese subjects from India11. In another study conducted by the authors’ group39, a diagnostic model for prediction of OSA was derived and validated in subjects presenting with non-sleep-related complaints at All India Institute of Medical Sciences (AIIMS), New Delhi. In this study, 102 subjects (group I, age range 31-70 years) presenting to the hospital with non-sleep-related complaints, none of whom had any significant co-morbid illness such as respiratory or congestive cardiac failure, underwent detailed evaluation. Using multivariate logistic regression analysis, a diagnostic model for prediction of OSA was derived. Subsequently, using similar selection criteria, another 104 subjects (group II, age range 32-68 years) were included for validation of the newly derived diagnostic model. BMI (kg/m²) [OR (95% CI), 1.14 (1.1-1.2)], male gender 5.0 (1.4-27.1), relative-reported snoring index (SI) 2.8 (1.7-5.0), and choking index (ChI) 8.1 (1.4-46.5) were found to be significant, independent predictors of OSA. The diagnostic model had an area under the receiver operator characteristics curve of 89.6%. A cutoff of 4.3 for the score was associated with sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 91.3%, 68.5%, 70.5%, and 92.3%, respectively. Misclassification rate with the application of the diagnostic model on group II subjects was 13.5% (14/104). Sensitivity, specificity, PPV, and NPV of the model for predicting OSA in this group were 82, 90.7, 89.1, and 84.5%, respectively39.

With increasing demand for diagnostic services, such models may help to select patients for further evaluation and may facilitate more efficient use of bed space in sleep laboratories. However, none of these models are a substitute for full PSG evaluation for the diagnosis of OSA.

Nocturnal Pulse Oximetry

Nocturnal pulse oximetry has been used to screen for OSA, and evidence is available suggesting that it may be useful in screening patients for PSG11. The sensitivity of nocturnal pulse oximetry in the diagnosis of OSA ranges from 31 to 98% and specificity from 41 to 100%32.

Polysomnography

Several forms of PSG such as full, attended, in-laboratory PSG, unattended PSG, portable PSG, have all been variously used for the diagnosis of OSA. Presently, attended, in-laboratory overnight full polysomnography where monitoring of various parameters reflecting respiration and monitoring cortical brain activity to assess the presence or absence of sleep and its stage are studied is considered the gold standard in the diagnosis of OSA. PSG is performed overnight in a sleep laboratory with a trained technician constantly monitoring the patient.

Apnea is defined as a greater than 90% cessation of airflow for ten or more seconds. Hypopnea is defined as a 50 to 90% reduction in airflow or a fall in percentage oxygen saturation of three or more or an arousal evident on electroencephalographic (EEG) recording. A respiratory event related arousal (RERA) is defined as increasing respiratory effort required to maintain a normal airflow culminating in an arousal on EEG.

Sometimes, split-night PSG is performed during a single night in the sleep laboratory, especially if the patient manifests AHI greater than 40 in the first two hours of the study. In the split-study, the baseline diagnostic portion is followed by therapeutic continuous positive airway pressure (CPAP) titration. The guidelines proposed by the American Sleep Disorders Association (ASDA) and classification of severity of OSA is shown in Table 53.

<table>
<thead>
<tr>
<th>Sleepiness</th>
<th>Sleep-related obstructive breathing events (apnea, hypopnea, and respiratory effort related arousals):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild: unwanted sleepiness or involuntary sleep</td>
<td>Mild: 5–15 events/hour of sleep</td>
</tr>
<tr>
<td>episodes occur during activities that require</td>
<td>Moderate: 15–30 events/hour of sleep</td>
</tr>
<tr>
<td>little attention</td>
<td>Severe: &gt; 30 events/hour of sleep</td>
</tr>
<tr>
<td>Moderate: unwanted sleepiness or involuntary</td>
<td></td>
</tr>
<tr>
<td>sleep episodes occur during activities that</td>
<td></td>
</tr>
<tr>
<td>require some attention</td>
<td></td>
</tr>
<tr>
<td>Severe: unwanted sleepiness or involuntary sleep</td>
<td></td>
</tr>
<tr>
<td>episodes occur during activities that require</td>
<td></td>
</tr>
<tr>
<td>active attention</td>
<td></td>
</tr>
</tbody>
</table>

Source: Reference 3
Metabolic Abnormalities

Several metabolic abnormalities have been described in patients with OSA. Critical evaluation of published evidence, however, suggests that OSA has no independent association with lipid abnormalities, insulin resistance, serum leptin, adiponectin and C-reactive protein measured by high sensitivity enzyme immunoassay (hs-CRP) levels. Obesity, and not OSA, appears to be responsible for these metabolic abnormalities.

Differential Diagnosis

OSA must be distinguished from other conditions associated with excessive sleepiness such as narcolepsy, idiopathic hypersomnia, hypothyroidism, depression, limb movement disorders like periodic limb movement disorder, restless leg syndrome, alcohol, drugs like sedatives, hypnotics, antidepressants, anticonvulsants, antihypertensives. Other conditions such as insufficient sleep time, insomnia, environmental disturbances, and inadequate sleep hygiene must also be distinguished from OSA by diligent clinical examination and judicious use of investigations.

MANAGEMENT

Modifiable risk factors including recent weight gain, alcohol, sedative/hypnotic use, cigarette smoking, and chronic nasal obstruction should be identified and corrected. Co-morbid medical conditions including systemic hypertension, atherosclerotic disease, heart failure, hypothyroidism, chronic lung disease, and neuromuscular disease that may be worsened by OSA should be diligently searched for and managed appropriately. An algorithm for treatment of OSA is shown in Fig. 1.

Conservative Treatment

Lifestyle Modification

While there are no randomized controlled trials endorsing the utility of lifestyle modification in the management of OSA, enough rationale exists supporting the view that lifestyle modification may be beneficial at least to the co-morbid illnesses that usually accompany OSA.

Weight Reduction

Because a decrease in body weight of as little as 10% has been associated with clinically significant improvement in the AHI, weight loss should be recommended to overweight patients with OSA. Other potential benefits of weight loss include its favorable impact on co-morbid conditions such as hypertension, heart failure, respiratory failure, insulin resistance and dyslipidaemia.

Avoidance of Alcohol and Respiratory Depressants

Alcohol selectively suppresses upper airway dilator muscle activity, increases inspiratory resistance during wakefulness and sleep and predisposes to OSA. Avoidance of alcohol and drugs such as hypnotics and sedatives is helpful in amelioration of the symptoms of OSA.

Cessation of Cigarette Smoking and Sleep Hygiene

Patients with OSA who are current cigarette smokers should be counselled to quit smoking. Poor sleep habits (referred to as hygiene) are among the most common problems encountered in the modern society. These
include staying up too late and getting up too early, interrupting sleep with work, drugs, chemicals, and late-night activities such as movies and television among others. Measures to improve sleep hygiene such as avoidance of caffeine and other stimulants, regular sleep-wake schedule, creating a comfortable undisturbed sleep environment, and avoidance of daytime napping should be advocated. Measures to Relieve Nasal Congestion

Measures to relieve nasal congestion include nasal corticosteroids, oral non-sedating antihistamines, and various surgical procedures too may contribute in the improvement of OSA especially when used under the supervision of an otolaryngologist.

Pharmacological Treatment

While a wide range of pharmacological agents have been used earlier, currently available evidence does not support the use of pharmacological agents in the treatment of OSA. Recently published evidence suggests that modafinil showed significant improvement in alertness and subjective and objective daytime sleepiness in patients with OSA who had residual sleepiness despite nasal CPAP therapy, thereby suggesting that this agent may have a role as adjunctive symptomatic therapy. These findings merit further detailed evaluation. As of now, there is insufficient evidence to recommend the use of drug therapy in the treatment of OSA.

Nasal Continuous Positive Airway Pressure (CPAP)

Nasal CPAP remains the most effective therapy for patients with OSA, especially those with daytime somnolence. CPAP eliminates upper-airway flow limitation by acting as a mechanical stent of the upper airway, stabilizing the upper airway, augmenting the lung volume and eliciting a reflex which increases upper airway dilator muscle tone. The American Academy of Sleep Medicine guidelines for CPAP therapy recommend its use for patients with an apnea index (mean number of apneas per hour of sleep) of greater than 20 and for symptomatic patients with AH1 or respiratory arousal index (mean number of arousals per hour of sleep) of greater than 10. A ‘titration’ study is performed over a single night with the therapeutic pressure determined as that which overcomes 90% or 95% of sleep-related events.

CPAP use has clearly been shown to have a favorable impact on daytime sleepiness in sleepy patients with OSAHS, driving performance as measured by driving simulators, and also accident rates. CPAP favorably modifies multiple factors at the neurophysiological and molecular levels which promote cardiovascular disease. Overall, about 70% of symptomatic patients use CPAP effectively and sufficiently to have a major impact on symptoms.

Bilevel Positive Airway Pressure (BiPAP)

Unlike CPAP which provides the same magnitude of pressure during the inspiratory and expiratory portions of the ventilatory cycle, bilevel positive airway pressure (BiPAP) permits independent adjustment of the inspiratory and expiratory positive airway pressures. In BiPAP, the inspiratory positive airway pressure (IPAP) level is set to prevent upper airway closure and partial obstruction (hypopnea) during the inspiratory phase of breathing. The expiratory positive airway pressure (EPAP) is set to stabilise the upper airway at end-expiration, such that the airway remains sufficiently patent to permit the patient to trigger delivery of IPAP by generating low level inspiratory volume or flow during the subsequent effort. The benefits of BiPAP include: providing ventilatory assistance and improved patient comfort. Anecdotal evidence suggests that BiPAP is better tolerated by some patients and may facilitate therapeutic salvage of patients who are intolerant of CPAP or in whom CPAP is inadequately effective.

Others

In addition to the conventional fixed pressure CPAP (F-CPAP), autotitrating CPAP (A-CPAP) has recently been introduced. Unlike F-CPAP, which must remain throughout the night at a sufficiently high level to maintain upper airway patency, A-CPAP levels fluctuate to accommodate the physiological requirements to maintain upper airway patency. The relative efficacy of these modalities of treatment merit further study.

Adverse effects of CPAP include those related to nasopharyngeal symptoms, those related to the interface or nasal route of delivery, and those specifically related to the magnitude of pressure. Nasopharyngeal symptoms are often amenable to local treatment measures. Interface-related problems can be resolved by careful and methodical assessment of all interface options and choosing the one that is most appropriately suited to the patient. Clinicians should be aware of the potential risk of raised intraocular pressure, barotrauma resulting in pneumothorax and pneumoencephalus.

Oral Appliance Therapy

Mandibular advancement devices that result in the protrusion of the mandible during sleep and thereby
reduce retroglossal airway collapse have been used in patients with mild apnea or non-apneic snoring and have been found to be beneficial. A multidisciplinary team approach including a dentist and/or orthodontist who understands the limitations of oral appliance therapy, is essential to facilitate the benefits associated with this form of treatment.

Surgery

Overall, the usefulness of surgery in the management of OSA remains ill-defined and is still controversial. Various surgical procedures aimed at relieving upper airway obstruction include: (i) resection of redundant soft tissue (nasal surgery, uvulopalatopharyngoplasty, laser assisted uvulopalatoplasty, midline glossectomy); (ii) induction of scar tissue formation (cautery or radio-frequency ablation of soft palate, tongue, or epiglottis); and (iii) displacement of bony and ligamentous attachments of upper airway soft tissue structures (maxillary and mandibular osteotomies, tongue and hyoid suspensions). In the emergency setting, tracheostomy may occasionally be required.

While specific obstructing lesions such as adenotonsillar enlargement should be surgically resected, the relative utility of these surgical procedures remains variable and should be confined to carefully designed clinical trials performed in centres with expertise in these complex surgical procedures.

Experimental Measures

Sleeping in lateral position has been recommended for mild positional OSA especially for patients who are not tolerating CPAP. Nocturnal electrical stimulation of the hypoglossal nerve by an implanted pace-maker has been attempted to prevent sleep related upper airway collapse by activating submandibular muscles. Intriguingly, regular didgeridoo playing has been reported to be an effective alternative treatment in patients with moderate OSA. Didgeridoo, classified by musicologists as an aerophone, is a wind instrument of the indigenous Australians of Northern Australia.

Conclusions

Early identification and treatment of OSA is associated with immense benefit to the patients. Education and sensitization of primary care physicians to screen for OSA is desired as it may facilitate referral to the specialist for PSG and diagnostic confirmation. Further research is warranted into the natural history, causes, and consequences of OSA. This will facilitate interventions to reduce or reverse OSA progression before the development of significant morbidity.

REFERENCES

40. Sharma SK, Kumpawat S, Goel A, Banga A, Ramakrishnan L, Chaturvedi P. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep disordered breathing. Sleep Med 2006 (accepted).
41. Sharma SK, Misra H, Sharma H, Goel A, Gulati V, Mohammed T. Obesity and not OSA is responsible for raised levels of serum hs-CRP. Sleep Med 2006 (submitted).


